# Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients

Study · id `cardio:ct-nct03579914` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03579914](<https://clinicaltrials.gov/study/NCT03579914>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03579914

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Heart failure; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1206 participants.

## Technical summary

Registry record NCT03579914. Randomized; no masking; primary purpose treatment. Start 2017-11-28 (actual); primary completion 2020-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1206 participants (enrolled count; ClinicalTrials.gov record NCT03579914, source copy `cardio:ctgov-nct03579914-2021-11-04`, retrieved 2026-10-26)
- Started: 2017-11-28 (actual) (ClinicalTrials.gov record NCT03579914, source copy `cardio:ctgov-nct03579914-2021-11-04`, retrieved 2026-10-26)
- Primary completion: 2020-08-31 (actual) (ClinicalTrials.gov record NCT03579914, source copy `cardio:ctgov-nct03579914-2021-11-04`, retrieved 2026-10-26)
- Completion: 2021-08-30 (actual) (ClinicalTrials.gov record NCT03579914, source copy `cardio:ctgov-nct03579914-2021-11-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03579914, source copy `cardio:ctgov-nct03579914-2021-11-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03579914-2021-11-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients
- Condition: Anterior Myocardial Infarction
- Condition: Heart Failure
- Intervention (Drug): intravenous Placebo
- Intervention (Drug): Metoprolol Injectable Product
- Intervention (Device): Romote Ischemic Conditioning (RIC)
- Intervention (Combination product): Metoprolol & RIC
- Lead sponsor: Harbin Medical University
- Lead sponsor class: OTHER
- Collaborator: Beijing Chao Yang Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Harbin Medical University (`cardio:org-harbin-medical-university`)
- Registry lists this organization as a collaborator: Beijing Chao Yang Hospital (`cardio:org-beijing-chao-yang-hospital`)

## Provenance

Content hash: 45e6830831d76bb887b91a60a3ac6656d69d39acd37aacc69ea5bc264bc6ec39
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
